Stockscreener 앱 받기
3.0745
1.29%
-0.0355
Agenus Inc 주식(AGEN)의 최신 뉴스
Agenus (AGEN) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Yahoo Finance
Agenus to Provide Corporate Update and First Quarter 2025 Financ - GuruFocus
Agenus To Provide Corporate Update And First Quarter 2025 Financial Report - marketscreener.com
Agenus to Provide Corporate Update and First Quarter 2025 Financial Report - Bluefield Daily Telegraph
Agenus' BOT/BAL Neoadjuvant Pan-Cancer Data from the NEOASIS Stu - GuruFocus
Breakthrough: Agenus BOT/BAL Cancer Treatment Achieves 90% Response Rate Across Multiple Tumors - Stock Titan
AGEN Investors Have Opportunity to Lead Agenus Inc. Securities Fraud Lawsuit - marketscreener.com
Press Release Distribution & PR Platform - ACCESS Newswire
Agenus' BOT/BAL Data in Pretreated Liver Cancer Presented at AAC - GuruFocus
Agenus’ BOT/BAL Data in Pretreated Liver Cancer Presented at AACR 2025 - The Joplin Globe
New Clinical Data: Agenus' BOT/BAL Achieves 72% Disease Control Rate in Treatment-Resistant Liver Cancer - Stock Titan
Peptide Cancer Vaccine Market Set to Witness Significant Growth - openPR.com
Agenus Announces Botensilimab and Balstilimab Presentations at A - GuruFocus
Breakthrough Cancer Drug Data: Agenus to Present 3 New Studies on Botensilimab at ASCO 2025 - Stock Titan
Agenus Announces Botensilimab and Balstilimab Presentations at ASCO 2025 - The Joplin Globe
Agenus (AGEN) Price Target Slashed by B. Riley Analyst, Buy Rati - GuruFocus
Agenus (AGEN) Price Target Slashed by B. Riley Analyst, Buy Rating Maintained | AGEN Stock News - GuruFocus
B. Riley Cuts Price Target on Agenus to $8 From $11, Keeps Buy Rating - marketscreener.com
Agenus Inc. (AGEN) to Present Key Cancer Research at AACR Meetin - GuruFocus
AGEN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Agenus Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
AGEN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Agenus Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
AGEN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Agenus Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Agenus stock hits 52-week low at $1.44 amid sharp annual decline - Investing.com Australia
Agenus stock hits 52-week low at $1.44 amid sharp annual decline By Investing.com - Investing.com South Africa
AGEN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Agenus Inc. and Encourages Investors to Contact the Firm Today! - ACCESS Newswire
Agenus Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before November 5, 2024 to Discuss Your RightsAGEN - ACCESS Newswire
Agenus stock hits 52-week low at $1.53 amid sharp annual decline By Investing.com - Investing.com South Africa
Agenus stock hits 52-week low at $1.53 amid sharp annual decline - Investing.com India
Breakthrough Cancer Treatment Data: Agenus BOT/BAL Shows Promise Across Multiple Cancers - Stock Titan
Here's Why Agenus (AGEN) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance
Agenus stock hits 52-week low at $1.64 amid sharp annual decline By Investing.com - Investing.com South Africa
Agenus stock hits 52-week low at $1.64 amid sharp annual decline - Investing.com Australia
Agenus Unveils Colorectal Cancer Survey Findings, Highlighting the Urgent Need for Treatment Innovation - Lelezard
93% of Doctors Say Current Colorectal Cancer Treatments Fall Short, New Study Shows - Stock Titan
H.C. Wainwright maintains neutral on Agenus stock post-10-K filing - Investing.com Australia
AGENUS INC SEC 10-K Report - TradingView
Gilead Sciences : Agenus Closes $150 Million Immuno-Oncology Transaction with Gilead - Marketscreener.com
Agenus (AGEN) Reports Q4 Loss, Lags Revenue Estimates - MSN
Equities Analysts Offer Predictions for Agenus Q1 Earnings - Defense World
HC Wainwright Reaffirms Neutral Rating for Agenus (NASDAQ:AGEN) - Defense World
Agenus stock falls after revenue miss - MSN
0.03%
0.49%
자본화:
|
볼륨(24시간):